CoChat

Proteasome subunit PSMC3 variants cause neurosensory syndrome combining deafness and cataract due to proteotoxic stress

Open access

Published version of a preprint

The DOI matches its Crossref record; 96 of the 96 references it cites were found in a registry or an index.

Abstract

The ubiquitin–proteasome system degrades ubiquitin‐modified proteins to maintain protein homeostasis and to control signalling. Whole‐genome sequencing of patients with severe deafness and early‐onset cataracts as part of a neurological, sensorial and cutaneous novel syndrome identified a unique deep intronic homozygous variant in the PSMC3 gene, encoding the proteasome ATPase subunit Rpt5, which lead to the transcription of a cryptic exon. The proteasome content and activity in patient's fibroblasts was however unaffected. Nevertheless, patient's cells exhibited impaired protein homeostasis characterized by accumulation of ubiquitinated proteins suggesting severe proteotoxic stress. Indeed, the TCF11/Nrf1 transcriptional pathway allowing proteasome recovery after proteasome inhibition is permanently activated in the patient's fibroblasts. Upon chemical proteasome inhibition, this pathway was however impaired in patient's cells, which were unable to compensate for proteotoxic stress although a higher proteasome content and activity. Zebrafish modelling for knockout in PSMC3 remarkably reproduced the human phenotype with inner ear development anomalies as well as cataracts, suggesting that Rpt5 plays a major role in inner ear, lens and central nervous system development.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.15252/emmm.201911861

Cites

96 of 96 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1 Family pedigree and cDNA analysis AFamily pedigree. Variant segregation analysis of PSMC3. Electropherogram of a part of intron 10 of PSMC3 encompassing the identified variation (c.[1127 + 337A>G];[1127 + 337A > G], p.[(Ser376Arg15*)];[(Ser376Arg15*)]) in the affected individuals, their unaffected parents and siblings. The variation was found at the homozygous state in the affected individuals (II.2, II.4, II.7) and at the heterozygous state in the parents (I.1, I.2, I.3, I.4, I.5, I.6) and was either at the heterozygous state (II.5) or absent in the unaffected siblings (II.1, II.3, II.6).BFace (up) and profile (down) photographs for patients II.4 (a: 8 yo, b: 16 yo), II.2 (c: 6 yo, d: 14 yo) and II.7 (e: 1 yo, f: 7 yo) over time. One can observe prominent supraciliary arches, synophrys, sunken cheeks, short philtrum and retrusion in the malar region.CSubcutaneous calcifications found only on knees (g: 9 yo and h: 16 yo) and on elbows (i: 9 yo) of patient II.4. White hair were present only on the legs of the 3 patients as illustrated for patient II.4 (j: 16 yo).DTemporal bone CT scan from patient II.7 (left column) and a control (right column) showing malformation of the semicircular canal. The left ear is shown on the upper panels while the right ear on the lower panels.EAmplification of the cDNA fragment between exons 9–10 and 11 of PSMC3 showing the abnormally spliced RNA fragment. One band at 180 bp representing the normal allele is seen for the control and two bands for the individual II.4 (pathologic allele at 300 bp).FSchematic representation for the incorporation of the 114 bp intronic sequence resulting from the c.1127 + 337A > G deep intronic variation on the mRNA. Sanger sequencing of the fragment between exons 9–10 and 11 of the PSMC3 cDNA obtained from patient II.4 fibroblasts’ RNA, showing the insertion of the 114 bp cryptic exon. As a comparison, the schematic representation and sequence from a control individual are shown above. Source data are available online for this figure.
Figure 1 Family pedigree and cDNA analysis AFamily pedigree. Variant segregation analysis of PSMC3. Electropherogram of a part of intron 10 of PSMC3 encompassing the identified variation (c.[1127 + 337A>G];[1127 + 337A > G], p.[(Ser376Arg15*)];[(Ser376Arg15*)]) in the affected individuals, their unaffected parents and siblings. The variation was found at the homozygous state in the affected individuals (II.2, II.4, II.7) and at the heterozygous state in the parents (I.1, I.2, I.3, I.4, I.5, I.6) and was either at the heterozygous state (II.5) or absent in the unaffected siblings (II.1, II.3, II.6).BFace (up) and profile (down) photographs for patients II.4 (a: 8 yo, b: 16 yo), II.2 (c: 6 yo, d: 14 yo) and II.7 (e: 1 yo, f: 7 yo) over time. One can observe prominent supraciliary arches, synophrys, sunken cheeks, short philtrum and retrusion in the malar region.CSubcutaneous calcifications found only on knees (g: 9 yo and h: 16 yo) and on elbows (i: 9 yo) of patient II.4. White hair were present only on the legs of the 3 patients as illustrated for patient II.4 (j: 16 yo).DTemporal bone CT scan from patient II.7 (left column) and a control (right column) showing malformation of the semicircular canal. The left ear is shown on the upper panels while the right ear on the lower panels.EAmplification of the cDNA fragment between exons 9–10 and 11 of PSMC3 showing the abnormally spliced RNA fragment. One band at 180 bp representing the normal allele is seen for the control and two bands for the individual II.4 (pathologic allele at 300 bp).FSchematic representation for the incorporation of the 114 bp intronic sequence resulting from the c.1127 + 337A > G deep intronic variation on the mRNA. Sanger sequencing of the fragment between exons 9–10 and 11 of the PSMC3 cDNA obtained from patient II.4 fibroblasts’ RNA, showing the insertion of the 114 bp cryptic exon. As a comparison, the schematic representation and sequence from a control individual are shown above. Source data are available online for this figure.CC BY · PubMed Central
Figure 2 Effect of the deep intronic PSMC3 variant on the proteasome function AAnti‐ubiquitin Western blot in control and patient fibroblasts and total amount of proteins loaded (stainfree) showing increased ubiquitination in patient cells (lane 4).BHistogram showing the quantification of ubiquitin with Western blot assays. The data shown correspond to the sum of all bands detected by the anti‐ubiquitin antibody expressed as a percentage of the amount of ubiquitin in “Control 1” cells. Bars show mean of ten independent experiments ± SD (n = 10, t‐test *P < 0.01, **P < 0.05).CMass spectrometry results from the co‐immunoprecipitation with PSMC3 are displayed as the normalized total number of spectra count of each protein computed as the mean from 3 controls (x axis) vs. the mean of patient II.4 triplicate. Proteasome subcomplexes are coloured according to the displayed legend, and standard ratio lines are drawn.
Figure 2 Effect of the deep intronic PSMC3 variant on the proteasome function AAnti‐ubiquitin Western blot in control and patient fibroblasts and total amount of proteins loaded (stainfree) showing increased ubiquitination in patient cells (lane 4).BHistogram showing the quantification of ubiquitin with Western blot assays. The data shown correspond to the sum of all bands detected by the anti‐ubiquitin antibody expressed as a percentage of the amount of ubiquitin in “Control 1” cells. Bars show mean of ten independent experiments ± SD (n = 10, t‐test *P < 0.01, **P < 0.05).CMass spectrometry results from the co‐immunoprecipitation with PSMC3 are displayed as the normalized total number of spectra count of each protein computed as the mean from 3 controls (x axis) vs. the mean of patient II.4 triplicate. Proteasome subcomplexes are coloured according to the displayed legend, and standard ratio lines are drawn.CC BY · PubMed Central
Figure 3 Fibroblasts derived from patient carrying the c.1127 + 337A>G homozygous PSMC3 variation exhibit an increased amount of both proteasome complexes and ubiquitin–protein conjugates AWhole‐cell lysates from control and patient (case index, CI) fibroblasts were assessed by 3–12% native‐PAGE gradient gels with proteasome bands (30S, 26S and 20S complexes) visualized by their ability to cleave the Suc‐LLVY‐AMC fluorogenic peptide.BTen micrograms of control and patient cell lysates was tested for their chymotrypsin‐like activity by incubating them with 0.1 mM of the Suc‐LLVY‐AMC substrate at 37°C over a 180‐h period of time in quadruplicates on a 96‐well plate. Indicated on the y‐axis are the raw fluorescence values measured by a microplate reader and reflecting the AMC cleavage from the peptide. Bars show the mean of 4 independent experiments ± SD.CProteasome complexes from control and patient fibroblasts separated by native‐PAGE were subjected to Western blotting using antibodies specific for α6, Rpt5 (PSMC3) and PA28‐α, as indicated.DProteins extracted from control and CI PSMC3 were separated by 10 or 12.5% SDS–PAGE prior to Western blotting using primary antibodies directed against ubiquitin and several proteasome subunits and/or components including α6, β1, β; β5, β5i, Rpt2 (PSMC1), Rpt5 (PSMC3), Rpt3 (PSMC4), Rpt4 (PSMC6) and PA28‐α, as indicated. For the PSMC3 staining, two exposure times are shown. Arrow indicates an additional PSMC3 species corresponding to the expected size of the truncated PSMC3 variant. Equal protein loading between samples was ensured by probing the membrane with an anti‐α‐Tubulin antibody. Source data are available online for this figure.
Figure 3 Fibroblasts derived from patient carrying the c.1127 + 337A>G homozygous PSMC3 variation exhibit an increased amount of both proteasome complexes and ubiquitin–protein conjugates AWhole‐cell lysates from control and patient (case index, CI) fibroblasts were assessed by 3–12% native‐PAGE gradient gels with proteasome bands (30S, 26S and 20S complexes) visualized by their ability to cleave the Suc‐LLVY‐AMC fluorogenic peptide.BTen micrograms of control and patient cell lysates was tested for their chymotrypsin‐like activity by incubating them with 0.1 mM of the Suc‐LLVY‐AMC substrate at 37°C over a 180‐h period of time in quadruplicates on a 96‐well plate. Indicated on the y‐axis are the raw fluorescence values measured by a microplate reader and reflecting the AMC cleavage from the peptide. Bars show the mean of 4 independent experiments ± SD.CProteasome complexes from control and patient fibroblasts separated by native‐PAGE were subjected to Western blotting using antibodies specific for α6, Rpt5 (PSMC3) and PA28‐α, as indicated.DProteins extracted from control and CI PSMC3 were separated by 10 or 12.5% SDS–PAGE prior to Western blotting using primary antibodies directed against ubiquitin and several proteasome subunits and/or components including α6, β1, β; β5, β5i, Rpt2 (PSMC1), Rpt5 (PSMC3), Rpt3 (PSMC4), Rpt4 (PSMC6) and PA28‐α, as indicated. For the PSMC3 staining, two exposure times are shown. Arrow indicates an additional PSMC3 species corresponding to the expected size of the truncated PSMC3 variant. Equal protein loading between samples was ensured by probing the membrane with an anti‐α‐Tubulin antibody. Source data are available online for this figure.CC BY · PubMed Central
Figure 4 Patient fibroblasts carrying the c.1127 + 337A>G homozygous PSMC3 variation exhibit an exhausted TCF11/Nrf1 processing pathway, which prevents them to upregulate proteasome subunits in response to proteotoxic stress Control and patient (index case, IC PSMC3) fibroblasts were exposed to a 16‐h treatment with 30 nM of the proteasome inhibitor carfilzomib or left untreated (as a negative control). Following treatment, cells were collected and subjected to RIPA‐mediated protein extraction prior to SDS–PAGE and subsequent Western blotting using antibodies specific for ubiquitin, TCF11/Nrf1, Rpt1 (PSMC2), Rpt3 (PSMC4), Rpt5 (PSMC3), Rpt6 (PSMC5), β1, β2, β5, β5i, β1i, PA28‐α and α‐Tubulin (loading control) as indicated. For the TCF11/Nrf1 staining, two exposure times are shown.Source data are available online for this figure.
Figure 4 Patient fibroblasts carrying the c.1127 + 337A>G homozygous PSMC3 variation exhibit an exhausted TCF11/Nrf1 processing pathway, which prevents them to upregulate proteasome subunits in response to proteotoxic stress Control and patient (index case, IC PSMC3) fibroblasts were exposed to a 16‐h treatment with 30 nM of the proteasome inhibitor carfilzomib or left untreated (as a negative control). Following treatment, cells were collected and subjected to RIPA‐mediated protein extraction prior to SDS–PAGE and subsequent Western blotting using antibodies specific for ubiquitin, TCF11/Nrf1, Rpt1 (PSMC2), Rpt3 (PSMC4), Rpt5 (PSMC3), Rpt6 (PSMC5), β1, β2, β5, β5i, β1i, PA28‐α and α‐Tubulin (loading control) as indicated. For the TCF11/Nrf1 staining, two exposure times are shown.Source data are available online for this figure.CC BY · PubMed Central
Figure 5 Overexpression of wild‐type PSMC3 in patient fibroblast restores intracellular protein homeostasis and prevents the loss of proteasome subunit expression in response to proteasome inhibition AControl and/or patient (index case, IC PSMC3) fibroblasts were subjected to a 24‐h transfection with pcDNA3.1/empty vector (mock) or pcDNA3.1/PSMC3 prior to RIPA‐mediated protein extraction and subsequent Western blotting using antibodies specific for ubiquitin, PSMC3 (i.e. Rpt5) and α‐Tubulin (loading control).BDensitometry analysis showing the relative ubiquitin contents detected by Western blotting in patient fibroblasts exposed to either pcDNA3.1/empty vector (mock) or pcDNA3.1/PSMC3, as indicated. The y‐axis represents the per cent changes in densitometry measurements (of pixel intensities using ImageJ), which are set as 100% for cells transfected with the pcDNA3.1/empty vector (mock) at 24 post‐transfection (n = 4, *P < 0.05, t‐test). Bars show the mean ± SEM.CPatient (index case, IC PSMC3) fibroblasts transfected with either pcDNA3.1/empty vector (mock) or pcDNA3.1/PSMC3 were exposed to a 30‐nM treatment of carfilzomib or left untreated (as a negative control). After 16 h, cells were collected and subjected to RIPA‐mediated protein extraction prior to SDS–PAGE and subsequent Western blotting using antibodies specific for ubiquitin, TCF11/Nrf1, Rpt1 (PSMC2), Rpt3 (PSMC4), Rpt5 (PSMC3), Rpt6 (PSMC5), β1, β2, β5, β5i, PA28‐α and α‐Tubulin (loading control), as indicated. For the TCF11/Nrf1 staining, two exposure times are shown. Source data are available online for this figure.
Figure 5 Overexpression of wild‐type PSMC3 in patient fibroblast restores intracellular protein homeostasis and prevents the loss of proteasome subunit expression in response to proteasome inhibition AControl and/or patient (index case, IC PSMC3) fibroblasts were subjected to a 24‐h transfection with pcDNA3.1/empty vector (mock) or pcDNA3.1/PSMC3 prior to RIPA‐mediated protein extraction and subsequent Western blotting using antibodies specific for ubiquitin, PSMC3 (i.e. Rpt5) and α‐Tubulin (loading control).BDensitometry analysis showing the relative ubiquitin contents detected by Western blotting in patient fibroblasts exposed to either pcDNA3.1/empty vector (mock) or pcDNA3.1/PSMC3, as indicated. The y‐axis represents the per cent changes in densitometry measurements (of pixel intensities using ImageJ), which are set as 100% for cells transfected with the pcDNA3.1/empty vector (mock) at 24 post‐transfection (n = 4, *P < 0.05, t‐test). Bars show the mean ± SEM.CPatient (index case, IC PSMC3) fibroblasts transfected with either pcDNA3.1/empty vector (mock) or pcDNA3.1/PSMC3 were exposed to a 30‐nM treatment of carfilzomib or left untreated (as a negative control). After 16 h, cells were collected and subjected to RIPA‐mediated protein extraction prior to SDS–PAGE and subsequent Western blotting using antibodies specific for ubiquitin, TCF11/Nrf1, Rpt1 (PSMC2), Rpt3 (PSMC4), Rpt5 (PSMC3), Rpt6 (PSMC5), β1, β2, β5, β5i, PA28‐α and α‐Tubulin (loading control), as indicated. For the TCF11/Nrf1 staining, two exposure times are shown. Source data are available online for this figure.CC BY · PubMed Central
Figure 6 psmc3 morphants and F0 mosaic zebrafish exhibit cataract and show abnormalities during the semicircular canal development in the ear AScheme of a zebrafish eye.B, B′Cataract detection revealed abnormal lens reflection in psmc3 morpholino (MO)‐mediated knockdown but not in controls (uninj, ctrl‐mo). Similarly, abnormal lens reflection was also observed in embryos injected with sgRNA + Cas9 but not in sgRNA‐injected embryos without Cas9 (sgRNA2). Co‐injection of wt psmc3 mRNA with either psmc3‐mo or sgRNA2 + Cas9 reduced the number of embryos presenting abnormal lens reflection. Scale bar = 50 μm. (B′) Quantification of embryos with abnormal lens reflection.CRepresentative image of a zebrafish ear at 4 dpf. kc = kinocilia.D, D′Brightfield images of inner ear development (lateral position). (D) Epithelial projections were fused and formed canal pillars in 4‐day‐old uninjected and control‐injected fish (ctrl‐mo, sgRNA2) but not in morphants (mo) and crispants (sgRNA2 + Cas9). Co‐injection of wt psmc3 mRNA with psmc3‐mo or sgRNA + Cas9 reduced the number of embryos presenting abnormal ear phenotype. Black asterisks indicate fused pillars. Red arrowheads mark unfused projections. Scale bar = 100 μm. (D′) Quantification of embryos with abnormal projection outgrowth.E, E′An anti‐acetylated tubulin antibody (green) staining revealed an abnormal amount of kinocilia in psmc3 crispants (sgRNA2 + Cas9) compared to uninjected and control‐injected embryos (sgRNA2). Nuclei are stained in blue with DAPI. Representative images show kinocilia of the lateral cristae. Scale bar = 20 μm. (E′) Quantification of embryos with an abnormal amount of kinocilia.
Figure 6 psmc3 morphants and F0 mosaic zebrafish exhibit cataract and show abnormalities during the semicircular canal development in the ear AScheme of a zebrafish eye.B, B′Cataract detection revealed abnormal lens reflection in psmc3 morpholino (MO)‐mediated knockdown but not in controls (uninj, ctrl‐mo). Similarly, abnormal lens reflection was also observed in embryos injected with sgRNA + Cas9 but not in sgRNA‐injected embryos without Cas9 (sgRNA2). Co‐injection of wt psmc3 mRNA with either psmc3‐mo or sgRNA2 + Cas9 reduced the number of embryos presenting abnormal lens reflection. Scale bar = 50 μm. (B′) Quantification of embryos with abnormal lens reflection.CRepresentative image of a zebrafish ear at 4 dpf. kc = kinocilia.D, D′Brightfield images of inner ear development (lateral position). (D) Epithelial projections were fused and formed canal pillars in 4‐day‐old uninjected and control‐injected fish (ctrl‐mo, sgRNA2) but not in morphants (mo) and crispants (sgRNA2 + Cas9). Co‐injection of wt psmc3 mRNA with psmc3‐mo or sgRNA + Cas9 reduced the number of embryos presenting abnormal ear phenotype. Black asterisks indicate fused pillars. Red arrowheads mark unfused projections. Scale bar = 100 μm. (D′) Quantification of embryos with abnormal projection outgrowth.E, E′An anti‐acetylated tubulin antibody (green) staining revealed an abnormal amount of kinocilia in psmc3 crispants (sgRNA2 + Cas9) compared to uninjected and control‐injected embryos (sgRNA2). Nuclei are stained in blue with DAPI. Representative images show kinocilia of the lateral cristae. Scale bar = 20 μm. (E′) Quantification of embryos with an abnormal amount of kinocilia.CC BY · PubMed Central
Figure 7 Schematic diagram depicting TCF11/Nrf1 processing pathway in response to proteasome dysfunction and/or proteotoxic stress in patient carrying the deep intronic homozygous PSMC3 variation (left) and in healthy subjects (right) Under normal conditions, TCF11/Nrf1 is a short‐lived ER membrane (endoplasmic reticulum)‐resident protein, which is rapidly subjected to proteasome‐mediated degradation following retro‐translocation to the cytosol by ER‐associated degradation machinery (ERAD). In case of proteasome dysfunction (i.e. proteotoxic stress), the half‐life of TCF11/Nrf1 is prolonged and become then a substrate for the NGLY1 and DDI2, thereby giving rise to a C‐terminal cleaved fragment that enters into the nucleus. After nuclear translocation, cleaved TCF11/Nrf1 associates with Maf and promotes the expression of proteasomes genes, so that protein homeostasis can be restored. In patients carrying the c.1127 + 337A>G homozygous PSMC3 variation, defective proteasomes promote a constitutive activation of TCF11/Nrf1, thereby resulting in increased assembly of newly synthetized non‐functional proteasomes, which in turn activate TCF11/Nrf1 again. Over‐activation of TCF11/Nrf1 results in pathway exhaustion thus rendering patient cells incapable of responding to further proteotoxic stress.
Figure 7 Schematic diagram depicting TCF11/Nrf1 processing pathway in response to proteasome dysfunction and/or proteotoxic stress in patient carrying the deep intronic homozygous PSMC3 variation (left) and in healthy subjects (right) Under normal conditions, TCF11/Nrf1 is a short‐lived ER membrane (endoplasmic reticulum)‐resident protein, which is rapidly subjected to proteasome‐mediated degradation following retro‐translocation to the cytosol by ER‐associated degradation machinery (ERAD). In case of proteasome dysfunction (i.e. proteotoxic stress), the half‐life of TCF11/Nrf1 is prolonged and become then a substrate for the NGLY1 and DDI2, thereby giving rise to a C‐terminal cleaved fragment that enters into the nucleus. After nuclear translocation, cleaved TCF11/Nrf1 associates with Maf and promotes the expression of proteasomes genes, so that protein homeostasis can be restored. In patients carrying the c.1127 + 337A>G homozygous PSMC3 variation, defective proteasomes promote a constitutive activation of TCF11/Nrf1, thereby resulting in increased assembly of newly synthetized non‐functional proteasomes, which in turn activate TCF11/Nrf1 again. Over‐activation of TCF11/Nrf1 results in pathway exhaustion thus rendering patient cells incapable of responding to further proteotoxic stress.CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 96 references

Cited by

See all 65

Metadata

Authors
Kröll‐Hermi, A., Ebstein, F., Stoetzel, C., Geoffroy, V., Schaefer, E., Scheidecker, S., Bär, S., Takamiya, M., Kawakami, K., Zieba, B. A., Studer, F., Pelletier, V., Eyermann, C., Speeg‐Schatz, C., Laugel, V., Lipsker, D., Sandron, F., McGinn, S., Boland, A., Deleuze, J., Kuhn, L., Chicher, J., Hammann, P., Friant, S., Etard, C., Krüger, E., Muller, J., Strähle, U., & Dollfus, H.
Affiliations
  • Karlsruhe Institute of Technology (DE)
  • Universitätsmedizin Greifswald (DE)
  • Inserm (FR)
  • Centre National de la Recherche Scientifique (FR)
  • National Institute of Genetics (JP)
  • Hôpitaux Universitaires de Strasbourg (FR)
  • Commissariat à l'Énergie Atomique et aux Énergies Alternatives (FR)
Corresponding author
  • Krüger, Elke
  • Muller, Jean
  • Strähle, Uwe
  • Dollfus, Hélène
Venue
EMBO Molecular Medicine
Published
2020-06-05
Volume
12
Issue
7
Pages
e11861-e11861
ISSN
  • 1757-4676 (ISSN-L)
  • 1757-4684
OpenAlex
W3034019369
Cited by
65
References
95
Citations by year
2026: 7 · 2025: 5 · 2024: 12 · 2023: 13 · 2022: 10 · 2021: 16 · 2020: 2
FWCI
3.33
Type
journal article
Language
en
Open access
Licence
Locations
  • EMBO Molecular Medicine (publishedVersion, other-oa)
  • bioRxiv (Cold Spring Harbor Laboratory) (acceptedVersion)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • HAL (submittedVersion, other-oa)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
  • Greater South Information System
Funders
  • Agence Nationale de la Recherche (ANR-10-LABX-0013)
  • Molecular Medicine Research Consortium of the University of Greifswald (FOVB-2018-11)
  • Fritz-Thyssen Foundation (Az. 10.16.2.022MN)
  • German Research Foundation (SFBTRR186 A13, SFBTRR 167 A04)
  • NBRP and NBRP/Fundamental Technologies Upgrading Program from AMED
  • JED-Belgique to Foundation
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Ubiquitin and proteasome pathways
  • Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Genetic Neurodegenerative Diseases
  • Life Sciences › Neuroscience › Sensory Systems › Hearing, Cochlea, Tinnitus, Genetics
Keywords
proteasome, proteotoxic stress, deafness, cataract, cryptic exons, intronic variants, proteostasis, ubiquitinated protein accumulation, inner ear development, lens development, zebrafish model, fibroblasts
MeSH terms
ATPases Associated with Diverse Cellular Activities, Adolescent, Animals, Cataract, Child, Child, Preschool, Consanguinity, Deafness, Female, Humans, Infant, Male, Mutation, Pedigree, Phenotype, Stress, Physiological, Syndrome, Zebrafish, Ubiquitin, Zebrafish Proteins, Proteasome Endopeptidase Complex, Nuclear Respiratory Factor 1, Proteolysis, Proteasome Inhibitors

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Proteasome subunit PSMC3 variants cause neurosensory syndrome combining deafness and cataract due to proteotoxic stress. https://app.cochat.ai/papers/10.15252/emmm.201911861
The paper
Kröll‐Hermi, A., Ebstein, F., Stoetzel, C., Geoffroy, V., Schaefer, E., Scheidecker, S., Bär, S., Takamiya, M., Kawakami, K., Zieba, B. A., Studer, F., Pelletier, V., Eyermann, C., Speeg‐Schatz, C., Laugel, V., Lipsker, D., Sandron, F., McGinn, S., Boland, A., . . . Dollfus, H. (2020). Proteasome subunit PSMC3 variants cause neurosensory syndrome combining deafness and cataract due to proteotoxic stress. EMBO Molecular Medicine. https://doi.org/10.15252/emmm.201911861

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.